

Catalysis Science & Technology

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: L. Xu, L. wang, X. xu and J. Lin, *Catal. Sci. Technol.*, 2019, DOI: 10.1039/C9CY01608B.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

14 **Abstract**

15 L-threonine transaldolase (LTTA) was a putative serine hydroxymethyltransferase
16 (SHMT) that could catalyze the trans-aldehyde reaction of L-threonine and aldehyde
17 to produce L-threo- β -hydroxy- α -amino acids with excellent stereoselectivity. In
18 present study, a L-threonine transaldolase from *Pseudomonas* sp. (PsLTTA) was
19 mined and expressed in *Escherichia coli* BL21 (DE3). Substrate spectrum assay
20 indicated that PsLTTA only consumed L-threonine as donor substrate and could
21 accept a wide range of aromatic aldehydes as acceptor substrates. Among those
22 substrates, PsLTTA could catalyze *p*-methylsulfonyl benzaldehyde and L-threonine to
23 produce L-threo-*p*-methylsulfonylphenylserine with high conversion (74.4%) and
24 high *de* value (79.9%). It was found that the conversion and stereoselectivity of
25 PsLTTA were dramatically influenced by concentration of whole-cell, co-solvent and
26 reaction temperature. By conditional optimization,
27 L-threo-*p*-methylsulfonylphenylserine was obtained with 67.1% conversion and near
28 perfect *de* value (94.5%), the highest stereoselectivity of L-threo- β -hydroxy- α -amino
29 acids reported by enzymatic synthesis so far. Finally, synthesis of
30 L-threo-*p*-methylsulfonylphenylserine in a 100 mL scale by a whole-cell biocatalyst
31 was conducted. This was for the first time systemically reported that L-threonine
32 transaldolase as a robust biocatalyst for preparation of β -hydroxy- α -amino acids
33 which could provide new insights for β -hydroxy- α -amino acids synthesis.

34

35 1. Introduction

36 β -hydroxy- α -amino acids composed of numerous important building blocks which
37 were essential for the synthesis of agriculturally or medicinally bioactive products.¹⁻³
38 For example, some β -hydroxy- α -amino acids such as
39 L-threo-*p*-methylsulfonylphenylserine and L-threo-*p*-nitrophenylserine were known
40 as key intermediates of thiamphenicol and chloramphenicol, respectively.^{4,5}
41 L-threo-phenylserine could be found in cyclomarin A, a marine cyclopeptide with
42 anti-tuberculosis and anti-malaria activities.⁶ In addition,
43 L-threo-3,4-dihydroxyphenylserine (Droxidopa) itself served as a crucial drug for the
44 treatment of Parkinson's disease.⁷ As a result, β -hydroxy- α -amino acids had attracted
45 extensive attentions because of their important role in chemical synthesis and
46 pharmaceutical manufacturing.

47 β -hydroxy- α -amino contained two-chiral centers and four isomers (L-threo, D-threo,
48 L-erythro and D-erythro) were produced simultaneously during the chemical
49 processes.^{8,9} This made optically pure of β -hydroxy- α -amino acid difficult to
50 synthesize. Many approaches including Sharpless asymmetric dihydroxylation,
51 epoxidation or enzymatic aldol addition had been developed for the synthesis of
52 β -hydroxy- α -amino acids.¹⁰⁻¹² Among them, enzymatic approach was most promising
53 as it could establish two new chiral-centers in a single reaction with inexpensive
54 substrates as well as under mild and unprotected conditions.¹² Threonine aldolases
55 (TAs) were such a kind of enzymes that catalyzed the aldol addition of glycine and
56 various aldehyde to produce β -hydroxy- α -amino acids. TA was a pyridoxal

57 5'-phosphate (PLP)-dependent enzyme and could be classified into LTA and DTA
58 based on the stereospecificity at the C_α of its products.¹³⁻¹⁵ In most cases, TA was
59 highly stereoselective (>99% enantiomeric excess, *ee*) at the C_α while showed
60 moderate stereoselectivity at the C_β (about 10-45% diastereomeric excess, *de*).¹⁶ As a
61 result, both threo and erythro isomers were produced in a TA-catalyzed reaction. This
62 “C_β problem” had greatly hampered and limited the synthetic application of TA. One
63 possible reason for the poor stereoselectivity at C_β was that two active histidine
64 residues in TA could both interact with the hydroxyl group on C_β from the opposite
65 direction.¹⁶ It was noteworthy that up to now, attempts to improve the C_β
66 stereoselectivity of TA by protein engineering had ended in failure mainly due to the
67 complicated interactions in the enzyme active center participating in the aldol addition
68 reactions.^{14,17,18} DTA was reported could obtain a high stereoselectivity by keeping
69 the reactions under kinetically control (usually in conditions of low temperature and
70 low amount of enzyme).^{19,20} Unfortunately, almost all of active intermediates were
71 L-threo isomers and only produced by LTA⁴⁻⁷. Recently, Chen et al. had developed a
72 high-throughput screening method and improved the stereoselectivity of LTA.
73 However, the *de* value of mutant enzyme was up to about 74% which was still too
74 low for the industrial application.¹⁸ As a result, the mining and characterization of
75 novel L-threonine aldolase-like enzyme with high stereospecificity was requisite to
76 meet the needs of industrial production as well as to expand toolkit for asymmetric
77 synthesis of β-hydroxy-α-amino acids.

78 In recent years, L-threonine transaldolase (LTTA) was reported as a member of
79 antibiotic gene cluster and participated in the biosynthesis of antibiotics.²¹⁻²³ The
80 characteristic of LTTA was that it could catalyze the formation of β -hydroxy- α -amino
81 acids with high stereoselectivity at C_{β} using L-threonine and aldehyde as substrates.²²
82 Phylogenetic analysis indicated that LTTA, LTA and serine hydroxymethyl
83 transferase (SHMT) shared a common evolutionary origin and thus might have a
84 similar catalytic mechanism.²² In present study, we characterized a LTTA form
85 *Pseudomonas* sp. with excellent stereoselectivity in β -hydroxy- α -amino acids
86 synthesis. It showed that PsLTTA only consumed L-threonine as donor substrate and
87 could accept a wide range of aromatic aldehydes as acceptor substrates. The
88 conversion and *de* value of L-threo-*p*-methylsulfonylphenylserine by PsLTTA were
89 up to 67.1% and 94.5% respectively after reaction conditions optimization. Finally,
90 synthesis of L-threo-*p*-methylsulfonylphenylserine in a 100 mL scale by a whole-cell
91 biocatalyst was conducted. Taken together, our results systematic evaluated the
92 catalytic property of PsLTTA and suggested that PsLTTA could serve as a promising
93 biocatalyst for preparation of L-threo- β -hydroxy- α -amino acids.
94

95 2. Results and discussion

96 2.1 Sequence analysis and expressing of PsLTTA

97 PsLTTA was identified as a SHMT-like enzyme as it showed about 26-33%
98 identity in amino acid sequence with SHMTs (Table S1).
99 Multiple sequences alignment demonstrated that the PLP-binding residues were quite
100 conservative among PsLTTA and SHMTs, suggesting that they might have a similar
101 catalytic mechanism (Fig S1). This was consistent with the previous report that LTTA
102 and SHMT shared a common evolutionary origin.²²

103 PsLTTA was inducing expressed under the optimum conditions (0.2 mM IPTG,
104 28°C, 16h) and further purified with His-tag affinity chromatography. The purified
105 PsLTTA revealed a pink color in solution (Fig S2A). SDS-PAGE indicated that most
106 of PsLTTA was soluble protein and its monomer molecular weight was about 48 kDa,
107 which was in accordance with the predicted molecular size (Fig S2B). PsLTTA could
108 catalyzed the trans-aldehyde reaction of L-threonine and aldehyde to produce
109 β -hydroxy- α -amino acids and acetaldehyde (Fig S3). Transaldolase activity assay
110 using *p*-methylsulfonyl benzaldehyde and L-threonine as substrates demonstrated that
111 the cell-free extracts and purified enzyme had specific activities of 0.87 U mg⁻¹ and
112 1.32 U mg⁻¹, respectively.

113 2.2 Enzymatic properties

114 Thermostability profile indicated that PsLTTA was quite stable in the range of
115 4-30°C. The enzymatic activity of PsLTTA was rapidly decreased when the
116 temperature was above 37°C and was complete inactivation at 60°C (Fig 1A). The

117 optimum reaction temperature of PsLTTA was determined at 30°C (Fig 1B). PsLTTA
118 was active at pH 6.0-8.0 as more than 80% activity could be detected (Fig 1C). The
119 maximum activity of PsLTTA was observed at 100 mM potassium phosphate buffer
120 with a pH value of 7.0 (Fig 1D). Those results suggested that PsLTTA was a pH and
121 temperature sensitive enzyme. The effects of metal ions on the activity of PsLTTA
122 were further investigated at concentrations of 1 mM and 10 mM. As shown in Fig 1E,
123 the transaldolase activity of PsLTTA was slightly promoted by Mg²⁺ and Li⁺ when
124 compared to the control group. Ni²⁺, Cu²⁺, Fe²⁺ and Zn²⁺ could inhibit PsLTTA both
125 in 1 mM and 10 mM. Other metal ions such as Cs²⁺, Ba²⁺, Ca²⁺ and Mn²⁺, showed
126 little effect on PsLTTA in 1 mM but a moderate inhibition in 10 mM. PLP
127 concentration assay suggested that PLP was required for the catalysis of PsLTTA
128 since a PLP-free group showed 65.8% activity compared to the control group (250
129 μM PLP) (Fig 1F). This result was similar to the previous report that LTTA was a
130 PLP-dependent enzyme.²⁴ The partial activity in PLP-free group was likely on
131 account that the enzyme itself combined with a portion of PLP during the process of
132 folding intracellularly.

133 2.3 Substrate specificity of PsLTTA

134 The donor substrate specificity of PsLTTA was evaluated with *p*-methylsulfonyl
135 benzaldehyde as the acceptor. The K_m and k_{cat} of PsLTTA using L-threonine as donor
136 substrate was 9.85 mM and 63.4 min⁻¹ while PsLTTA was not active toward
137 L-allo-threonine, D-threonine, D-allo-threonine, L-serine and glycine (Table S2 and
138 Fig S4). Similar to the enzyme assay results, HPLC analysis indicated that PsLTTA

139 could catalyze *p*-methylsulfonyl benzaldehyde and L-threonine to form
140 L-threo-*p*-methylsulfonylphenylserine with high stereoselectivity (80.1% *de*) (Fig 2A).
141 However, no products were detected when using L-allo-threonine, D-threonine,
142 D-allo-threonine, and glycine as donor substrates (Fig 2C-2F). PsLTTA could also
143 catalyze the trans-aldehyde action of *p*-methylsulfonyl benzaldehyde and L-serine,
144 however, the transaldolase activity sharply declined and the major product was
145 L-erythro-*p*-methylsulfonylphenylserine (-43.8% *de*) (Fig 2B). Those data suggested
146 that PsLTTA was high selective in donor substrate. Coincidentally, the configuration
147 of L-threonine was L-threo form which was the same as the major product, this
148 finding let us speculated that the strict donor specificity might contribute to the high
149 stereoselectivity of PsLTTA.

150 The acceptor substrate specificity was further assessed using L-threonine as the
151 donor. We evaluated the catalytic activity of PsLTTA on aliphatic aldehydes such as
152 formaldehyde or acetaldehyde. The results showed that PsLTTA could not consume
153 those two aldehydes mainly due to their oxidability. It demonstrated that PsLTTA
154 could utilize a wide range of aromatic aldehydes as acceptor substrate to produce
155 β -hydroxy- α -amino acids. As expected, all the major products were L-threo forms
156 (Table 1). This was quite important since the active intermediates of thiamphenicol,
157 chloramphenicol and Droxidopa were L-threo isomers.⁴⁻⁷ We found the substituent
158 type on the phenyl ring of aromatic aldehydes could affect the activity of PsLTTA.
159 For example, PsLTTA could catalyze aromatic aldehydes with electron-withdrawing
160 substituents such as -CH₃SO₂, -NO₂, -F, -Cl and -Br, while electron-donating

161 substituents (-CH₃, -OCH₃ and -OH) could not serve as the substrates of PsLTTA. For
162 -Cl and -Br substituted benzaldehydes, it showed that PsLTTA only catalyzed
163 *o*-substituted benzaldehydes, suggesting that the position of substituent also had an
164 effect on PsLTTA. Those results were quite similar when using DTA to catalyze
165 aromatic aldehydes and glycine. Chen et al. reported that the type of substituting as
166 well as the position on the phenyl ring played an essential role in the catalytic
167 performance of DTA by affecting the interaction between the β-OH-group of the
168 substrate and the manganese ion during the process of substrate recognition.²⁰ This
169 conclusion seemed to be useful for PsLTTA and could be the basis for protein
170 engineering of PsLTTA.

171 It was worth mentioning that PsLTTA could catalyze *p*-methylsulfonyl
172 benzaldehyde with a high conversion (74.4%) and high stereoselectivity (79.9% *de*).
173 The product L-threo-*p*-methylsulfonylphenylserine was the main intermediate of
174 thiamphenicol and florfenicol. L-threonine aldolase (LTA) also reported that could
175 catalyze the formation of *p*-methylsulfonylphenylserine using *p*-methylsulfonyl
176 benzaldehyde and glycine as substrates.²⁵ We assessed the catalytic activity and
177 stereoselectivity of PsLTTA and a LTA from *Clavibacter michiganensis* (CILTA).
178 The conversion of *p*-methylsulfonyl benzaldehyde by PsLTTA and CILTA were 75.2%
179 and 85.6%, respectively. However, the *de* value of
180 L-threo-*p*-methylsulfonylphenylserine by PsLTTA was 79.6%, much higher than that
181 of CILTA with a *de* value of 28.6% (Fig S5). This result suggested that PsLTTA was
182 more stereoselective compared to CILTA. Furthermore, the reverse activities of

183 PsLTTA and CILTA were evaluated using L-threo-*p*-methylsulfonylphenylserine as
184 substrate. As shown in Fig S6, CILTA could total change
185 L-threo-*p*-methylsulfonylphenylserine into *p*-methylsulfonyl benzaldehyde and
186 glycine within 3 hours. This result was consistence with the conclusion that
187 LTA-catalyzed reaction was reversible.²⁶ To our surprise, the reverse transaldol
188 activity of PsLTTA was almost undetectable when using
189 L-threo-*p*-methylsulfonylphenylserine and acetaldehyde as substrates, suggesting the
190 LTA-catalyzed reaction might not a reversible reaction. In LTA catalyzed-reaction,
191 the excess substrate (usually glycine was 10 folds to aldehyde) was required to make
192 sure that the reaction equilibrium shifted in the direction of producing
193 β -hydroxy- α -amino acids, which resulted in a waste of substrates.¹⁸ In PsLTTA, the
194 use of superfluous substrates could be avoidable as its poor reverse transaldol activity.
195 Considering the stereoselectivity and substrate availability, it revealed that PsLTTA
196 was more suitable for industrialized application of producing β -hydroxy- α -amino
197 acids.

198 **2.4 Effects of reaction conditions on conversion and stereoselectivity of PsLTTA**

199 Although the enzyme activity assay indicated that PsLTTA achieved the
200 maximum activity at phosphate buffer (Fig 1D), it revealed that the transformation of
201 β -hydroxy- α -amino acid by whole-cell biocatalyst could be improved more than 30%
202 when using Tris-HCl buffer (100 mM Tris-HCl, pH 7.0) as reaction buffer. This result
203 suggested Tris-HCl buffer was more suitable for whole-cell biocatalyst and was used
204 in the following reactions. 10% acetonitrile (v/v) was selected for co-solvent since

205 *p*-methylsulfonyl benzaldehyde dissolved well in acetonitrile and the
206 optimal reaction temperature (30 °C) was used as initial reaction temperature.

207 We first evaluated the concentration of wet cells (3 to 50 mg/ml) and substrate (10
208 to 40 mM) on the conversion and stereoselectivity of PsLTTA using *p*-methylsulfonyl
209 benzaldehyde and L-threonine as substrates. As shown in Fig 3, similar trends were
210 constantly observed that the increase of wet cells led to a decrease of stereoselectivity
211 in PsLTTA under different substrate concentration. The *de* values of products were
212 about 86.1% when the wet cells concentrations were 3.0 and 6.25 mg/ml. Then the *de*
213 values declined from 86.1% to 72.0% with the increase of wet cells concentrations
214 from 6.25 up to 50 mg/ml. Those results strongly indicated that low dose of wet cells
215 contributed to the formation of L-threo isomer. The 3.0 and 6.25 mg/ml of wet cells
216 concentrations had little difference in the stereoselectivity of PsLTTA, but greatly
217 affected its conversion (about 5-22% improvement in conversions), suggesting that
218 6.25 mg/ml of wet cells was suitable for achieving high stereoselectivity performance.
219 The concentration of substrates affected the conversion of PsLTTA but not its
220 stereoselectivity. Under 6.25 mg/ml wet cells concentration, the conversions fall from
221 90.1% to 50.5% when the substrate concentrations ranged from 10 mM to 40 mM.
222 We found that the products could reach the maximum yield at 30 mM substrate with a
223 conversion of 69.5%. Based on those results, 6.25 mg/ml and 30 mM were selected as
224 the final concentration of wet cells and substrate, respectively.

225 The effects of co-solvents were further investigated. As shown in Table 2, the none
226 organic solvents group gave a comparatively low conversion (41.6%) and *de* value

227 (71.3%), suggesting that organic solvents were required for the catalysis of PsLTTA.
228 It demonstrated that low percentage of organic solvents (10%) greatly promoted the
229 conversion of PsLTTA while high percentage of organic solvents (30%) led to a
230 decline of conversion. Among the tested organic solvents, high conversion (80.4%)
231 and *de* value (90.2%) were obtained when using 10% ethyl acetate as co-solvents. 10%
232 MeOH and 10% DMSO exerted promotion effects on the conversion but showed little
233 enhancements on the stereoselectivity of PsLTTA when compared to 10% CH₃CN
234 group. The addition of 10% acetone and 10% EtOH groups both lowered the
235 conversion and the stereoselectivity of PsLTTA. Thus, 10% ethyl acetate was selected
236 as an optimal co-solvent for enzymatic reaction.

237 The trans-aldehyde reaction of PsLTTA was evaluated under different temperature
238 for 6 hours. As shown in Fig 4, the highest conversion of products (79.8%) were
239 observed at 30°C, which was consistent with the conclusion that the optimum
240 reaction temperature of PsLTTA was 30°C. For stereoselectivity, we surprisingly found
241 that increasing temperature from 10°C to 35°C led to a reduction of stereoselectivity in
242 PsLTTA. The *de* values had little change (about 94.5%) but the conversion rates were
243 rapidly increased from 44.7% to 67.8% at the temperature of 10, 15 and 20 °C,
244 respectively. The *de* values sharply declined (from 94.5% to 87.2%) when the
245 temperature was 25, 30 and 37°C. Those results indicated that lower temperature
246 contributed to the formation of L-threo isomer and suggested 20 °C as the best
247 temperature for catalysis reaction of PsLTTA.

248 Taken together, our results strongly suggested that low concentration of wet cells

249 (6.25 mg/ml), co-solvent (10% ethyl acetate) and low temperature (20 °C) could
250 dramatically improve the stereoselectivity of PsLTTA with a *de* value from 71.3% up
251 to 94.5%. Our conclusion that low concentration of wet cells and low temperature
252 contributed to the stereoselectivity of PsLTTA was exactly similar to DTA.²⁰ Under
253 such conditions, the catalysis reaction was under kinetic control but not
254 thermodynamic control which was benefit for producing L-threo isomer.²⁷

255 In recent years, lots of attentions were put on TAs as they were the only reported
256 aldolases for production β -hydroxy- α -amino acids using cheap substrates (glycine and
257 aldehyde) and under mild conditions. However, the poor stereoselectivity at C $_{\beta}$ (about
258 10-45% *de*) severely blocked its industrialized application.¹⁶ In present study, the
259 characterized PsLTTA not only displayed TAs-like merits such as inexpensive
260 substrates and mild conditions, but also excellent stereoselectivity at C $_{\beta}$ (94.5% *de*)
261 and poor reverse transaldol activity. Under the optimized conditions, we further
262 assessed the stereoselectivity of PsLTTA and CILTA on other aromatic aldehydes
263 (Table 3 and Fig S7-14). Similar to *p*-methylsulfonyl benzaldehyde, PsLTTA could
264 consume multiple aromatic aldehydes to produce β -hydroxy- α -amino acids with
265 excellent stereoselectivity. Among those products, L-threo-*p*-nitrophenylserine (92.8%
266 *de*), L-threo-phenylserine (89.1% *de*), L-threo-*o*-chlorophenylserine (87.1% *de*) and
267 L-threo-*o*-bromophenylserine (86.9% *de*) were obtained with excellent
268 stereoselectivity. The *de* values of those products were much higher than that
269 catalyzed by PsLTTA before reaction optimization (Table 2) or by CILTA (Fig
270 S7-14). Those results demonstrated that the optimized reaction conditions were

271 universally applicable for aromatic aldehydes with different substituents. Considering
272 that L-threo-*p*-nitrophenylserine was widely reported as an intermediate of
273 chloramphenicol and L-threo-phenylserine could be found in several bioactive
274 substances,⁴⁻⁶ it strongly suggested that PsLTTA might take TA's place as a
275 promising and robust biocatalyst for production of useful β -hydroxy- α -amino acids.

276 2.5 Synthesis of L-threo-*p*-methylsulfonylphenylserine by whole-cell biocatalyst

277 A 100-mL scale reaction was then carried out under the optimal reaction conditions,
278 and time courses of transformation of L-threo-*p*-methylsulfonylphenylserine were
279 monitored from 0 to 24 h. As expected, L-threo-*p*-methylsulfonylphenylserine were
280 produced with excellent stereoselectivity (90.4% *de*). The conversion rate was 67.1%
281 and the concentration of *p*-methylsulfonyl benzaldehyde decreased from 31.0 mM to
282 10.2 mM within 24 hours. The synthesis of L-threo-*p*-methylsulfonylphenylserine
283 reached 13 mM (95.1% *de*) during the first 2 hours indicated that the beginning
284 reaction was efficient. The products added up to 21 mM at 12 h and was not increased
285 in yield from 12 to 24 h. However, the *de* value at 12 h was 93.1% and decreased to
286 90.4% at 24 h. In our opinion, L-threo-*p*-methylsulfonylphenylserine was synthesized
287 preferentially in the initial reaction stage. As time went by, the reaction tended to
288 produce more L-erythro-*p*-methylsulfonylphenylserine which led to a decline of *de*
289 value. Those results suggested that short time reaction contributed to the formation of
290 L-threo-*p*-methylsulfonylphenylserine. Considering that
291 L-threo-*p*-methylsulfonylphenylserine was instable, we changed it into
292 L-threo-*p*-methylsulfonylphenylserine ethyl ester by esterification. The final purified

293 product was 189 mg in white solid, yield 33.0% and further confirmed by HRMS (Fig
294 S15), ^1H NMR (Fig S16) and ^{13}C NMR (Fig S17) analysis. As far as we knew, these
295 results represent the highest *de* value reported far for asymmetric catalysis of
296 L-threo-*p*-methylsulfonylphenylserine.

297

298 3. Conclusions

299 A L-threonine transaldolase from *Pseudomonas* sp. (PsLTTA) was mined and
300 expressed in *Escherichia coli* BL21 (DE3). Substrate spectrum assay indicated that
301 PsLTTA only consumed L-threonine as donor substrate and could accept a wide range
302 of aromatic aldehydes as acceptor substrates. Through reaction condition optimization,
303 the reaction was under kinetic control and L-threo-*p*-methylsulfonylphenylserine was
304 obtained with more than 60% conversion and near perfect stereoselectivity (94.5% *de*),
305 the highest stereoselectivity of L-threo- β -hydroxy- α -amino acids reported by
306 enzymatic synthesis so far. Finally, synthesis of
307 L-threo-*p*-methylsulfonylphenylserine in a 100 mL scale by a whole-cell biocatalyst
308 was conducted. It was for the first time systematically demonstrated that L-threonine
309 transaldolase as a powerful biocatalyst for preparation of L-threo- β -hydroxy- α -amino
310 acids. However, it should be admitted that the production of
311 L-threo-*p*-methylsulfonylphenylserine by PsLTTA was comparatively low since the
312 maximum concentration was only about 20 mM under the optimized conditions. In
313 our opinion, the moderate production by PsLTTA mainly due to its
314 less-efficient catalytic ability. Furthermore, the produced acetaldehyde during the

315 reaction could also inhibit the synthesis of L-threo-*p*-methylsulfonylphenylserine
316 (data were not shown). So further studies such as engineering PsLTTA or establishing
317 an acetaldehyde removal system was under way to improve
318 L-threo- β -hydroxy- α -amino acids production.

319

320

321 **4. Experimental**

322 **4.1 Materials**

323 *Escherichia coli* BL21 (DE3) and plasmid pET28a were kept in our laboratory and
324 served as host strain and expression vector, respectively. Yeast alcohol dehydrogenase
325 (ADH), Pyridoxal 5'-phosphate (PLP) and NADH were purchased from Aladdin
326 (China). O-phthaldialdehyde (OPA) and N-acetyl-cysteine (NAC) were obtained from
327 Sigma-Aldrich (America). L-threo-*p*-methylsulfonylphenylserine standard was
328 purchased from Shanghai yuanye Bio-Technology Co., Ltd (China). All other
329 chemicals and reagents used in this work were obtained commercially with the
330 highest purity unless otherwise stated.

331 **4.2 Gene cloning, expression and purification**

332 The DNA sequences of *Pseudomonas* sp. L-threonine transaldolase (PsLTTA) and
333 *Clavibacter michiganensis* low specificity L-threonine aldolase (CILTA) based on
334 their protein sequences (GenBank No. WP_065936857 and WP_011931605) were
335 optimized and synthesized by Wuhan GeneCreate Biological Engineering Co., Ltd.
336 (China) and cloned into plasmid pET28a. The recombinant plasmids were further

337 transformed into *E. coli* BL21 (DE3).

338 500 mL *E. coli* BL21 (DE3) cells harbouring pET28a-*PsLTTA* or pET28a-*CILTA*
339 were grown in LB medium containing 50 µg/ mL kanamycin. The expression of
340 *PsLTTA* and *CILTA* were induced overnight at 28°C with 0.2 mM
341 isopropyl-β-D-thiogalactopyranoside (IPTG) after OD_{600 nm} reached 0.5. Cells were
342 pelleted at 6000 g under 4°C and were resuspended with Tris-HCl buffer (100 mM
343 Tris-HCl, 200 mM NaCl, 25 mM imidazole, pH 7.0). Cells were lysed by
344 ultrasonication and the soluble *PsLTTA* protein was purified by a Ni-IDA Prepacked
345 Column (Sangon, China) according to the instruction manual. The purified enzyme
346 was exchanged into Tris-HCl buffer (100 mM Tris-HCl, 20% glycerol, pH 7.0) by a
347 PD-10 desalination column (GE Healthcare, America) and further assessed by
348 SDS-PAGE. Protein concentration was determined using a BCA Protein Assay Kit
349 (Beyotime, China). For whole cell biocatalyst, wet cells were collected, weighted and
350 resuspended in Tris-HCl buffer (100 mM Tris-HCl, pH 7.0) with a concentration of
351 250 mg/ml. The purified enzymes and wet cells were stored at -80°C until used.

352 4.3 Enzyme activity assay

353 Enzyme activities of *PsLTTA* was determined by an NADH coupled with ADH
354 assay as previous described.²⁸ The reduction of NADH was detected by monitoring
355 the decrease in absorbance at 340 nm ($\epsilon=6220 \text{ M}^{-1}\text{cm}^{-1}$) using Multiskan Go
356 microplate reader (Thermo Scientific, America) at 25 °C. Reaction mixtures (180 µL)
357 consisting of 10 mM *p*-methylsulfonyl benzaldehyde, 30 mM L-threonine, 0.2 mM
358 PLP, 0.2 mM NADH and 10 U ADH in Tris-HCl buffer (100 mM Tris-HCl, pH 7.0,

359 10% acetonitrile) were incubated at 25 °C for 1 min. Reactions were initiated by
360 introduction of 10 mg PsLTTA enzyme (in 20 µL Tris-HCl buffer) and monitored at
361 340 nm for 2 min. A boiled enzyme sample was used as a negative control. One unit
362 (U) of transaldolase activity was defined as the amount of enzyme catalyzing the
363 conversion of 1 µmol of *p*-methylsulfonylphenylserine per minute.²⁹ All experiments
364 were conducted in triplicate.

365 4.4 Determination of kinetic parameters

366 The kinetic parameters were determined by measuring the initial rate of enzymatic
367 reaction at 10 mM *p*-methylsulfonyl benzaldehyde and varying concentrations of
368 L-threonine (0.1-200 mM).²⁹ Five independent replicates were performed for each
369 concentration of L-threonine assay and the data were fitted to the Michaelis-Menten
370 equation using Origin 8.0 software.

371 4.5 Effect of temperature and pH on the stability and activity of PsLTTA

372 The pH stability of PsLTTA was evaluated by investigating the transaldolase
373 ability after incubation in 4°C for 12h at various pHs using 100 mM citric acid-citrate
374 (pH 3.0-6.0), phosphate (pH 6.0-8.0), Tris-HCl (pH 8.0-9.0) and
375 carbonate-bicarbonate (pH 9.0-11.0) as buffer. The thermostability of enzyme was
376 assessed after 1h incubation at varied temperatures from 4 to 80°C.

377 The pH dependence of enzyme activity was studied at various pHs (pH 6.0-8.0) in
378 100 mM phosphate buffer. The effect of temperature on enzyme activity was assessed
379 at varied temperatures from 25 to 45 °C. The enzyme activity was measured as
380 described above. All experiments were conducted in triplicate.

381 **4.6 Effect of metal ions on transaldolase activity of PsLTTA**

382 The influences of different metal ions on transaldolase activity of PsLTTA were
383 studied in the presence of specific metal ions at final concentrations of 1 mM and 10
384 mM. The activity measured in the absence of metal ion was taken as a negative
385 control and all experiments were performed in triplicate.

386 **4.7 Chiral derivatization analysis of stereospecificity of PsLTTA**

387 The standard catalysis reaction was performed in 1 ml volume comprising 100 mM
388 L-threonine, 40 mM *p*-methylsulfonyl benzaldehyde, 0.2 mM PLP, 1 mM MgCl₂ and
389 2 μM PsLTTA (or 25mg/ml wet cells) in Tris-HCl buffer (100 mM Tris-HCl, pH 7.0).
390 Reaction was incubated at 30°C for 4h with constantly shaking and terminated by
391 addition of 2 ml MeOH. The reaction mixtures were incubated at 4°C for 12 h and the
392 supernatant was used for further study.

393 The determination of conversion and stereospecificity of PsLTTA was performed
394 by HPLC after derivatization with O-phthaldialdehyde/N-acetyl-cysteine
395 (OPA/NAC).³⁰ Briefly, the OPA/NAC reagent was obtained by dissolving of 100 mg
396 of NAC in 20 mL derivatization buffer (0.2 M Boric acid, 0.2 M KCl) and then 25.6
397 mg of OPA in 5 mL MeOH was added. OPA/NAC reagent was mixed with diluted
398 reaction solution at a ratio of 4:1 and kept for 10 min in room temperature.
399 Chromatographic analysis was carried out using Shimadzu LC-20AT HPLC system
400 (Japan) with an UV detector at 236 and 340 nm. Column: Agilent ZORBAX
401 reversed-phase columns (250×4.6 mm, 5 μm), mobile phase: 50 mM KH₂PO₄, pH
402 8.0/acetonitrile (81/19 or 79/21), flow rate: 1 ml min⁻¹, temperature: 30 °C.

403 **4.8 Donor and acceptor substrate specificity**

404 Donor substrate specificity of PsLTTA was evaluated using L-threonine,
405 L-allo-threonine, D-threonine, D-allo-threonine, L-serine and glycine as donors while
406 *p*-methylsulfonyl benzaldehyde as acceptor. For acceptor substrate specificity,
407 a series of aromatic aldehydes and L-threonine were selected as acceptor and donor,
408 respectively. Reaction mixtures were detected by enzyme activity assay or by
409 analytical HPLC after OPA/NAC derivatization.

410 **4.9 Effect of reaction condition on activity and stereospecificity of PsLTTA**

411 Effect of reaction conditions on whole-cell biocatalyst were further determined.
412 The initial catalysis condition was performed at 30°C for 3h, in a 1 ml volume
413 comprising 100 mM L-threonine, 40 mM *p*-methylsulfonyl benzaldehyde, 0.2 mM
414 PLP, 1 mM MgCl₂ and 25 mg wet cells in Tris-HCl buffer (100 mM Tris-HCl, 10%
415 CH₃CN, pH 7.0). The reaction conditions including amount of enzyme or substrate,
416 co-solvents and reaction temperature were further evaluated. The conversion and
417 stereospecificity catalyzed by whole-cell biocatalyst were detected by analytical
418 HPLC after OPA/NAC derivatization.

419 **4.10 Reverse activity of PsLTTA**

420 The reverse activity of PsLTTA was assessed using
421 L-threo-*p*-methylsulfonylphenylserine and acetaldehyde as substrates. The reaction
422 was performed in 1 ml volume comprising 100 mM
423 L-threo-*p*-methylsulfonylphenylserine, 50 mM acetaldehyde, 0.2 mM PLP, 1 mM
424 MgCl₂ and 25mg/ml wet cells in Tris-HCl buffer (100 mM Tris-HCl, pH 7.0).

425 Reaction was incubated at 30°C for different hours with constantly shaking and
426 terminated by addition of 2 ml MeOH. The conversions were detected by analytical
427 HPLC at 236 nm. The reaction catalyzed by CILTA was performed as a positive
428 control.

429 **4.11 Synthesis of L-threo-*p*-methylsulfonylphenylserine in a large scale of 100** 430 **mL system by whole-cell biocatalyst**

431 Transformation of L-threo-*p*-methylsulfonylphenylserine at a 100 mL system by
432 whole-cell biocatalyst were performed at the optimized reaction conditions. Briefly,
433 L-threonine (1.2 g, 10 mmol), *p*-methylsulfonyl benzaldehyde (0.55 g, 3 mmol), PLP
434 (5 mg, 0.02 mmol), MgCl₂ (10 mg, 0.1 mmol) and wet cells (0.625g) were added in
435 100 ml Tris-HCl buffer (100 mM Tris-HCl, 10% ethyl acetate, pH 7.0). The reaction
436 mixture was constantly shaking at 20 °C for 24 h. Time course of catalysis processing
437 was minored in triplicate. The conversion and stereoselectivity were detected by
438 analytical HPLC after OPA/NAC derivatization.

439 After reaction, the crude reaction supernatant was added 20 mL ethanol and
440 adjusted to pH 1.0 by concentrated sulfuric acid. For esterification, the mixture was
441 incubated at 100°C for 2 hours. The supernatant was extracted with chloroform twice.
442 The chloroform layer was combined and evaporated to dryness. The residue was
443 purified by a C18 SPE column (CHCl₃: MeOH = 2 :1) to give 189 mg white solid,
444 yield 33.0%. ¹H NMR (400 MHz, CDCl₃) δ 7.96 (d, *J* = 8.1 Hz, 2H), 7.62 (d, *J* = 8.1
445 Hz, 2H), 4.98 (d, *J* = 4.5 Hz, 1H), 4.19 (q, *J* = 7.0 Hz, 2H), 3.64 (d, *J* = 4.7 Hz, 1H),
446 3.08 (s, 3H), 1.23 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 172.79, 147.58,

447 139.91, 127.48, 127.26, 73.41, 61.64, 60.22, 44.53, 14.08. HRMS (m/z) (M^+): calcd.

448 for $C_{12}H_{18}NO_5S$, 288.0897, found 288.0900.

449

450 **Conflicts of interest**

451 There are no conflicts of interest to declare.

452 **Acknowledgements**

453 We thank Dr. Bing-De Zheng (College of Chemistry, Fuzhou University) for the
454 technical assistance of HRMS and NMR analysis. This study is financially supported
455 by Industry University Research project of Fuzhou University (No. 2019090501).

456

457 **References**

- 458 1. M. Hibi, T. Kasahara, T. Kawashima, H. Yajima, S. Kozono, S. V. Smirnov, J.
459 Ogawa, *Advanced Synthesis & Catalysis*, 2015, **357**, 767-774.
- 460 2. J. Steinreiber, K. Fesko, C. Mayer, C. Reisinger, M. Schürmann and H. Griengl,
461 *Tetrahedron*, 2007, **63**, 8088-8093.
- 462 3. S. F. Beaudoin, M. P. Hanna, I. Ghiviriga, J. D. Stewart, *Enzyme and microbial*
463 *technology*, 2018, **119**, 1-9.
- 464 4. G. H. Zhao, H. bLi, W. Liu, W. G. Zhang, F. Zhang, Q. Liu, Q. C. Jiao, *Amino*
465 *acids*, 2011, **40**, 215-220.
- 466 5. I. B. Seiple, J. A. Mercer, R. J. Sussman, Z. Zhang, A. G. Myers, *Angewandte*
467 *Chemie International Edition*, 2014, **53**, 4642-4647.
- 468 6. P. Barbie and U. Kazmaier, *Organic letters*, 2015, **18**, 204-207.

- 469 7. H. J. Gwon and S. H. Baik, *Biotechnology letters*, 2010, **32**, 143.
- 470 8. A. Geranurimi and W. D. Lubell, *Organic letters*, 2018, **20**, 6126-6129.
- 471 9. O. A. Levitskiy, Y. K. Grishin, T. V. Magdesieva, *European Journal of Organic*
472 *Chemistry*, 2019, **20**, 3174-3182.
- 473 10. H. C. Kolb, M. S. VanNieuwenhze, K. B. Sharpless, *Chemical Reviews*, 1994,
474 **948**, 2483-2547.
- 475 11. T. Katsuki and K. B. Sharpless, *Journal of the American Chemical Society*, 1980,
476 **102**, 5974-5976.
- 477 12. J. P. Adams, M. J. Brown, A. Diaz-Rodriguez, R. C. Lloyd, G. D. Roiban,
478 *Advanced Synthesis & Catalysis*, 2019, **361**, 2421-2432.
- 479 13. M. L. Di Salvo, S. G. Remesh, M. Vivoli, M. S. Ghatge, A. Paiardini, S.
480 D'Aguanno, R. Contestabile, *The FEBS journal*, 2014, **281**, 129-145.
- 481 14. K. Fesko, *Applied microbiology and biotechnology*, 2016, **100**, 2579-2590.
- 482 15. Y. L. Du and K. S. Ryan, *Natural product reports*, 2019, **36**, 430-457.
- 483 16. J. Blesl, M. Trobe, F. Anderl, R. Breinbauer, G. A. Strohmeier, K. Fesko,
484 *ChemCatChem*, 2018, **10**, 3453-3458.
- 485 17. K. Fesko, D. Suplatov, V. Švedas, *FEBS open bio*, 2018, **8**, 1013-1028.
- 486 18. Q. Chen, X. Chen, J. Feng, Q. Wu, D. Zhu, Y. Ma, *ACS Catalysis*, 2019, **9**,
487 4462-4469.
- 488 19. K. Fesko, C. Reisinger, J. Steinreiber, H. Weber, M. Schürmann, H. Griengl,
489 *Journal of Molecular Catalysis B: Enzymatic*, 2008, **52**, 19-26.
- 490 20. Q. Chen, X. Chen, Y. Cui, J. Ren, W. Lu, J. Feng, D. Zhu, *Catalysis Science &*

491 *Technology*, 2017, **7**, 5964-5973.

View Article Online
DOI: 10.1039/C9CY01608B

492 21. R. Ushimaru and H. W. Liu, *Journal of the American Chemical Society*, 2019,
493 **141**, 2211-2214.

494 22. T. A. Scott, D. Heine, Z. Qin, B. Wilkinson, *Nature communications*, 2017, **8**,
495 15935.

496 23. J. E. Schaffer, M. R. Reck, N. K. Prasad, T. A. Wencewicz, *Nature chemical*
497 *biology*, 2017, **13**, 737.

498 24. S. Barnard-Britson, X. Chi, K. Nonaka, A. P. Spork, N. Tibrewal, A. Goswami,
499 S. G. Van Lanen, *Journal of the American Chemical Society*, 2012, **134**,
500 18514-18517.

501 25. K. Baer, N. Dückers, T. Rosenbaum, C. Leggewie, S. Simon, M. Krauß, H.
502 Gröger, *Tetrahedron: Asymmetry*, 2011, **22**, 925-928.

503 26. Fesko, K. *Frontiers in bioengineering and biotechnology*, 2019, **7**, 119.

504 27. K. Fesko, G. A. Strohmeier, R. Breinbauer, *Applied microbiology and*
505 *biotechnology*, 2015, **99**, 9651-9661.

506 28. S. L. Goldberg, A. Goswami, Z. Guo, Y. Chan, M. A. Schmidt, *Organic Process*
507 *Research & Development*, 2015, **19**, 1308-1316.

508 29. S. Barnard-Britson, X. Chi, K. Nonaka, A. P. Spork, N. Tibrewal, A. Goswami,
509 S. G. Van Lanen, *Journal of the American Chemical Society*, 2012, **134**,
510 18514-18517.

511 30. J. Steinreiber, K. Fesko, C. Reisinger, M. Schürmann, F. van Assema, M.
512 Wolberg, H. Griengl, *Tetrahedron*, 2007, **63**, 918-926.

514 **Table**

515 **Table 1.** Acceptor substrate specificity of PsLTTA.

516 **Table 2.** Effects of co-solvents on the conversion and stereoselectivity of PsLTTA.

517 **Table 3** Stereoselectivity of PsLTTA and CILTA.

518

519 **Figure captions**

520 **Fig. 1.** Enzymatic properties of PsLTTA. (A) Temperature stability profile of
521 PsLTTA after incubation of enzyme solution on various temperatures (4-80 °C) for 60
522 minutes. (B) Detection of the optimal reaction temperature of PsLTTA. (C) pH
523 stability profile of PsLTTA after incubation of enzyme solution on various pH (3-11)
524 for 12 hours at 4°C. (D) Detection of the optimal reaction pH of PsLTTA. (E) Effects
525 of metal ions (1 mM and 10 mM) on the trans-aldehyde activity of PsLTTA. (F)
526 Effects of PLP concentration on the trans-aldehyde activity of PsLTTA. All assays
527 were performed three times.

528 **Fig. 2.** Donor substrate specificity of PsLTTA detected by HPLC after OPA/NAC
529 derivatization. (A) L-threonine. (B) L-serine. (C) D-threonine. (D) L-allo-threonine.
530 (E) D-allo-threonine. (F) glycine. Product L-*p*-methylsulfonylphenylserine ($t_{L\text{-threo}}=7.1$
531 min, $t_{L\text{-erythro}}=8.4$ min)

532 **Fig. 3.** Concentration effect of wet cells and substrates on the conversion and
533 stereoselectivity of PsLTTA. The concentrations of *p*-methylsulfonyl benzaldehyde
534 were 10 mM (A), 20 mM (B), 30 mM (C) and 40 mM (D), respectively. The reactions
535 mixture contained 10% (v/v) CH₃CN as co-solvent and incubation at 30 °C for 4

536 hours.

537 **Fig. 4.** Effect of temperature on the conversion and stereoselectivity of PsLTTA. (A)

538 The conversion and *de* value of L-threo-*p*-methylsulfonylphenylserine under various

539 temperatures. (B) Determination of stereospecificity of PsLTTA by HPLC analysis


540 after OPA/NAC derivatization. Product L-*p*-methylsulfonylphenylserine ($t_{L\text{-threo}}=7.1$

541 min, $t_{L\text{-erythro}}=8.4$ min).

542 **Fig. 5.** Time course for synthesis of L-threo-*p*-methylsulfonylphenylserine in 100 mL

543 scale.

544

545 **Table 1.** Acceptor substrate specificity of PsLTTA.View Article Online
DOI: 10.1039/C9CY01608B


R	Conversion (%)	de (%)	R	Conversion (%)	de (%)
H	51.0	77.2	<i>o</i> -Br	43.3	80.8
<i>o</i> -NO ₂	40.5	50.2	<i>m</i> -Br	ND	ND
<i>m</i> -NO ₂	25.2	29.9	<i>p</i> -Br	ND	ND
<i>p</i> -NO ₂	59.4	76.7	<i>p</i> -MeSO ₂	74.4	79.9
<i>o</i> -F	43.5	69.2	<i>p</i> -I	ND	ND
<i>m</i> -F	44.6	66.4	<i>o</i> -OH	ND	ND
<i>p</i> -F	ND	ND	<i>m</i> -OH	ND	ND
<i>o</i> -Cl	37.9	80.3	<i>p</i> -OH	ND	ND
<i>m</i> -Cl	ND	ND	<i>o</i> -CH ₃	ND	ND
<i>p</i> -Cl	ND	ND	<i>p</i> -O(CH ₃)	ND	ND

546 Reaction conditions: 1 mL reaction mixture containing 40 mM aromatic aldehydes,

547 100 mM L-threonine, 0.2 mM PLP, 1 mM MgCl₂ and 25 mg/mL wet cells in548 Tris-HCl buffer (100 mM Tris-HCl, 10% CH₃CN, pH 7.0) at 30 °C for 4 h.

549 ND, Not detected.

550

551

552 **Table 2.** Effects of co-solvents on the conversion and stereoselectivity of PsLTTA.

co-solvents	Conversion (%)	de (%)	co-solvents	Conversion (%)	de (%)
none	41.6	71.3	10% CH ₃ CN	70.4	84.9
10% MeOH	81.1	85.3	20% CH ₃ CN	45.1	82.1
20% MeOH	76.9	86.9	30% CH ₃ CN	26.2	79.0
30% MeOH	44.6	82.6	10% DMSO	78.2	84.2
10% EtOH	45.1	80.8	20% DMSO	69.9	85.7
20% EtOH	55.9	81.0	30% DMSO	56.0	84.6
30% EtOH	17.7	80.2	10% Ethyl acetate	80.4	90.2
10% Acetone	64.5	80.0	20% Ethyl acetate	74.8	89.4
20% Acetone	46.2	85.1	30% Ethyl acetate	69.2	89.4
30% Acetone	39.7	84.5	40% Ethyl acetate	61.1	89.9

553 Reaction conditions: 1 mL reaction mixture containing 30 mM *p*-methylsulfonyl
554 benzaldehyde, 100 mM L-threonine, 0.2 mM PLP, 1 mM MgCl₂ and 6.25 mg/mL wet
555 cells in Tris-HCl buffer (100 mM Tris-HCl, pH 7.0) at 30 °C for 4 h.

556 **Table 3** Stereoselectivity of PsLTTA and CILTA.View Article Online
DOI: 10.1039/C9CY01608B

R	<i>de</i> (%)		R	<i>de</i> (%)	
	PsLTTA	CILTA		PsLTTA	CILTA
H	89.1	17.0	<i>o</i> -F	78.1	38.5
<i>o</i> -NO ₂	77.7	35.0	<i>m</i> -F	80.4	20.4
<i>m</i> -NO ₂	67.9	25.6	<i>o</i> -Cl	87.1	53.9
<i>p</i> -NO ₂	92.8	28.3	<i>o</i> -Br	86.9	53.8

557 Reaction conditions:

558 For PsLTTA, 1 mL reaction mixture containing 30 mM aromatic aldehydes, 100 mM

559 L-threonine, 0.2 mM PLP, 1 mM MgCl₂ and 6.25 mg/mL wet cells in Tris-HCl buffer

560 (100 mM Tris-HCl, 10% ethyl acetate, pH 7.0) at 20 °C for 6 h.


561 For CILTA, 1mL reaction mixture containing 30 mM aromatic aldehydes, 300 mM

562 Glycine, 0.2 mM PLP and 6.25 mg/mL wet cells in Tris-HCl buffer (100 mM

563 Tris-HCl, 10% ethyl acetate, pH 7.0) at 20 °C for 6 h.

564


565 Fig 1.



566

567


568 Fig 2.

View Article Online
DOI: 10.1039/C9CY01608B

569

570


571 Fig 3.



572

573


574 Fig 4.

View Article Online
DOI: 10.1039/C9CY01608B

575

576


577 Fig 5.

View Article Online
DOI: 10.1039/C9CY01608B

578

579

580 Figure abstract

View Article Online
DOI: 10.1039/C9CY01608B

581